NKCx Histopathological outcome* within 12 months after cervix cytology in 2021 |
551 Örebro |
Benign | LSIL | HSIL | AIS | Cancer | Other | PAD missing | Total | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cytologi | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel |
Benign sample | 23 | 2.4% | 19 | 2.0% | 4 | 0.4% | 1 | 0.1% | . | . | 8 | 0.8% | 916 | 94.3% | 971 | 100.0% |
ASCUS | 194 | 31.6% | 162 | 26.4% | 34 | 5.5% | 1 | 0.2% | . | . | 49 | 8.0% | 174 | 28.3% | 614 | 100.0% |
LSIL | 92 | 21.3% | 135 | 31.3% | 70 | 16.2% | . | . | . | . | 32 | 7.4% | 102 | 23.7% | 431 | 100.0% |
Atypical glandular cells/AGC | 1 | 14.3% | 1 | 14.3% | . | . | 4 | 57.1% | 1 | 14.3% | . | . | . | . | 7 | 100.0% |
Unclear atypia | 6 | 30.0% | 3 | 15.0% | 7 | 35.0% | 1 | 5.0% | . | . | 2 | 10.0% | 1 | 5.0% | 20 | 100.0% |
ASC-H | 1 | 33.3% | . | . | 2 | 66.7% | . | . | . | . | . | . | . | . | 3 | 100.0% |
HSIL | 3 | 3.1% | 12 | 12.5% | 71 | 74.0% | 2 | 2.1% | 4 | 4.2% | 3 | 3.1% | 1 | 1.0% | 96 | 100.0% |
Totalt | 320 | 14.9% | 332 | 15.5% | 188 | 8.8% | 9 | 0.4% | 5 | 0.2% | 94 | 4.4% | 1194 | 55.7% | 2142 | 100.0% |
NOTE: Histopathological outcome from T83x taken into account. |
This list includes only one diagnosis (the highest ranking) per person, applies to both Cyt and Pad. |
* Harmonization of PAD codes classification between analysis registry and process registry has been carried out. PAD Class 0 (non diagnostic, unreasonable diagnosis) is excluded, and next PAD counts instead. |
The classes 2a, b, c and 3a (suspected premalignant, pre-malignant UNS, HPV, suspected malignant) are grouped into 'Other'. |
Process Registry's Class 1 (benign), 2d (LSIL) and 3b (manifest cancer) have all been introduced without exception. Some codes that occur beyond the scope of the process registry has been added to the different categories. |
Snomed codes in the category Cancer: |
---|
M80703, M81403 |